Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (TSV:TLT)

0.2050 +0.0150 (+7.89%)
Streaming Delayed Price Updated: 3:55 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,000
Open 0.1950
Bid (Size) 0.2000 (1,575)
Ask (Size) 0.2050 (45)
Prev. Close 0.1900
Today's Range 0.1950 - 0.2050
52wk Range 0.1550 - 0.3350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Topics Derivatives
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile

Performance

YTD
-25.5%
-25.5%
1 Month
+7.9%
+7.9%
3 Month
-2.4%
-2.4%
6 Month
+17.1%
+17.1%
1 Year
-19.6%
-19.6%

More News

Read More
Theralase(R) Releases 2Q2025 Financial Statements
Via Newsfile
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
Theralase(R) Extends Warrants
Via Newsfile
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
Theralase Completes Annual General and Special Meeting
Via Newsfile
Theralase Annual General Meeting
Via Newsfile
Theralase(R) 1Q2025 Financial Statements
Via Newsfile
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Via Newsfile
Theralase to Present Groundbreaking Research at ASTRO 2025
Via Newsfile
Theralase Provides Corporate Update
Via Newsfile
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Via Newsfile
Theralase Discovers New Mechanism of Action of Lead Drug
Via Newsfile
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Via Newsfile
Ruvidar Demonstrates 7 Year Complete Response
Via Newsfile
Ruvidar Effective in the Treatment of Herpes
Via Newsfile
Theralase(R) Releases 2024 Annual Financial Statements
Via Newsfile
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Via Newsfile
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Via Newsfile
Topics Death
Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Via ACCESS Newswire

Frequently Asked Questions

Is Theralase Technologies Inc publicly traded?
Yes, Theralase Technologies Inc is publicly traded.
What exchange does Theralase Technologies Inc trade on?
Theralase Technologies Inc trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Theralase Technologies Inc?
The ticker symbol for Theralase Technologies Inc is TLT on the Toronto Venture Stock Exchange
What is the current price of Theralase Technologies Inc?
The current price of Theralase Technologies Inc is 0.2050
When was Theralase Technologies Inc last traded?
The last trade of Theralase Technologies Inc was at 10/30/25 03:55 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.